You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Faron ESMO 2025

By Inderes
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights.